In a population-based study of over 61,000 adults with type 2 diabetes, discontinuing sodium-glucose cotransporter-2 inhibitors after a urinary tract infection did not reduce recurrence but increased cardiovascular and renal risks. Patients who developed a urinary tract infection had over threefold higher rates of major cardiovascular events and more than double the risk of renal complications. Stopping therapy raised cardiovascular and all-cause mortality by up to 50%, highlighting the importance of maintaining sodium-glucose cotransporter-2 inhibitor treatment when clinically appropriate.

Source: European Heart Journal